PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 14, 2026Current Signal Transduction Therapy0 citations

Pursuit of Neurotherapeutics in Alzheimer’s Treatment - A Comprehensive Review

View Full Paper
PYPrasanna Raju YalavarthiRARekha Devi AllagaddaDYD Yuvasri

Key Points

  • This review aims to explore the pathological mechanisms of Alzheimer's disease and evaluate current and emerging treatments.
  • Examined pathological features of Alzheimer's Disease such as amyloid-beta aggregation and tau protein hyperphosphorylation.
  • Analyzed the roles of various receptors in cognitive dysfunction and neurodegeneration.
  • Conducted a comprehensive review of treatment strategies targeting cholinergic and glutamate pathways.
  • Confirmed amyloid-beta plaques and tau protein tangles as key features of Alzheimer's pathology.
  • Current treatments focus on cholinergic and glutamate pathways while exploring new therapies like monoclonal antibodies and neuroprotective compounds.
  • Lifestyle interventions are also noted as beneficial strategies for risk reduction.

Abstract

Introduction: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, characterized by cognitive decline, memory loss, behavioral changes, and communication impairments. It presents a significant public health burden with social, economic, and healthcare implications. Despite extensive research, its etiology remains incompletely understood, necessitating therapeutic strategies rooted in pathological mechanisms. Methods: This study explores the pathological features of AD, including amyloid-beta aggregation, tau protein hyperphosphorylation, oxidative stress, mitochondrial dysfunction, and cholinergic deficits. It also examines the role of metabotropic and ionotropic glutamate receptors, acetylcholine receptors, NMDA receptors, and insulin receptors in cognitive dysfunction and neurodegenerative pathways. A comprehensive review of current and emerging treatment strategies targeting cholinergic and glutamate pathways is conducted. Results: The pathological hallmark of AD is the accumulation of amyloid-beta plaques and tau protein tangles, leading to neuronal dysfunction. Current treatment strategies focus on cholinergic and glutamate pathways, while monoclonal antibodies, anti-inflammatory agents, neuroprotective compounds, and stem cell-based therapies show promise in addressing disease progression. Lifestyle interventions and risk reduction strategies are also considered viable approaches. Discussion: Challenges persist in effectively reducing amyloid-beta plaque formation and tau protein aggregation. Despite ongoing advancements, the complexity of AD pathology necessitates further exploration into its molecular mechanisms and therapeutic interventions. Conclusion: This study provides insights into AD pathology and therapeutic advancements, offering a foundation for future neurotherapeutic research. Continued investigation is essential to develop effective treatments for this debilitating disease.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yalavarthi et al. (2026) studied this question.

synapsesocial.com/papers/69b4fbb1b39f7826a300c1a2https://doi.org/10.2174/0115743624411654251203063035
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pathological mechanisms and treatment progression of Alzheimer’s disease2025 · 69 citations
  2. 2Bridging the gaps in alzheimer’s disease: a comprehensive review of current and emerging therapies2026 · 3 citations
  3. 3Neurodegeneration in Alzheimer’s disease: A narrative review of mechanistic insights and emerging therapeutic approaches2025 · 1 citations
  4. 4Revolutionizing Therapeutic Approaches Against Pathophysiology of Alzheimer's Disease: A Therapeutic Review2025 · 3 citations
  5. 5Current and emerging therapeutic approaches in Alzheimer’s disease2026